Lymphoma, Mantle-Cell: all 810 studies
Page 1 of 9. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingNCT07892027Phase 2
- Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.Not yet recruitingNCT07883941Phase 1
- A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell LymphomaNot yet recruitingNCT07855016Phase 2
- A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaNot yet recruitingNCT07799220Phase 2
- A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell LymphomaRecruitingNCT07788118Phase 1/2
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingNCT07784101Phase 3
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingNCT07763210Phase 2
- Glofitamab in B-NHL Using Mid-Therapy Intratumoral TranscriptomicsNot yet recruitingNCT07748364Phase 2
- Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)RecruitingNCT07719556Phase 2
- Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor TherapyNot yet recruitingNCT07711327
- HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell LymphomaNot yet recruitingNCT07697339Phase 1
- A Study of ARC-02 in B-cell NHLRecruitingNCT07691606Phase 1
- Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyNot yet recruitingNCT07684950Phase 2
- Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaRecruitingNCT07673367Phase 2
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingNCT07609862Phase 1/2
- Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK InhibitorsNot yet recruitingNCT07592481Not applicable
- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07578077Phase 1/2
- Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCLNot yet recruitingNCT07569965Phase 2
- Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse EventEnrolling by invitationNCT07499128Not applicable
- A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell MalignanciesNot yet recruitingNCT07476378Not applicable
- Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07460362Phase 2
- Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell TherapyRecruitingNCT07453095Phase 2
- A Study of APG-3288 in Relapsed/Refractory Blood CancersRecruitingNCT07424833Phase 1
- This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including RNot yet recruitingNCT07412405Not applicable
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07377578Phase 3
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell TherapyRecruitingNCT07341191Phase 2
- Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaRecruitingNCT07285590Phase 2
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingNCT07272499Phase 2
- ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical TrialNot yet recruitingNCT07264894Phase 4
- Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaRecruitingNCT07261163Phase 2
- Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaRecruitingNCT07257510Not applicable
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 1
- PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell LymphomaNot yet recruitingNCT07207785Phase 2
- Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT AssessmentNot yet recruitingNCT07206264Phase 2
- Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRecruitingNCT07199296Phase 2
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasEnrolling by invitationNCT07168486Phase 1
- This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin LymphomaRecruitingNCT07121946Phase 1
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )RecruitingNCT07101328Phase 1
- A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)RecruitingNCT07082686Phase 2
- Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingNCT07077512Phase 2
- A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainRecruitingNCT07029737Phase 2
- JWCAR239 in Patients With B Cell Non-Hodgkin LymphomaNot yet recruitingNCT07024147Phase 1
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyRecruitingNCT07003295Phase 2
- Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT06980116Phase 1
- Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06859008Phase 1
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaRecruitingNCT06854003Phase 2
- CD70-targeted immunoPET Imaging of Malignant CancersRecruitingNCT06852638Phase 2
- Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaRecruitingNCT06846489Phase 2
- Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaRecruitingNCT06839053Phase 2
- A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788652
- Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T TreatmentRecruitingNCT06784167
- Real-world Study of AcalabrutinibEnrolling by invitationNCT06767891
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingNCT06742996Phase 3
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.RecruitingNCT06697184Phase 1/2
- Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06675123Phase 1
- A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingNCT06656221Phase 2
- Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell LymphomaRecruitingNCT06572618Phase 2
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingNCT06564038Phase 1/2
- Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaRecruitingNCT06558604Phase 2
- Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLRecruitingNCT06553872Phase 2
- SynKIR-310 for Relapsed/Refractory B-NHLRecruitingNCT06544265Phase 1
- A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.RecruitingNCT06542250Phase 1/2
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)RecruitingNCT06533579Phase 1/2
- Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingNCT06496308Phase 3
- CAR-T-cell Treatment for Untreated High Risk MANtle Cell LymphomaRecruitingNCT06482684Phase 2
- Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell LymphomaRecruitingNCT06464861Phase 1
- This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaNot yet recruitingNCT06427213Phase 2
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Phase 3
- Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL TrialRecruitingNCT06357676Phase 1/2
- A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell LymphomaRecruitingNCT06341556Phase 2
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasRecruitingNCT06340737Phase 1
- Italian Observational Study on CAR-T Therapy for LymphomaRecruitingNCT06339255
- Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.Not yet recruitingNCT06324994Phase 2
- Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT06263491Phase 2
- A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma PatientsNot yet recruitingNCT06255704Phase 2
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06252675Phase 2
- Preliminary Assessment of [18F]BL40 in PET/CT ScansRecruitingNCT06224309
- CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 1
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingNCT06191887Phase 1
- Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT StudyRecruitingNCT06151730
- A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaRecruitingNCT06136351Phase 2
- Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06054776Phase 2
- Patient Perspectives in Mantle Cell Lymphoma Clinical ResearchNot yet recruitingNCT06049472
- A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell MalignanciesRecruitingNCT06045910Phase 1/2
- Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsRecruitingNCT06043011
- Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingNCT06029309Phase 1/2
- CD79b-19 CAR T Cells in Non-Hodgkin LymphomaRecruitingNCT06026319Phase 1
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.RecruitingNCT06022029Phase 1
- ZR2 Sequential Immunochemotherapy for Newly Treated MCLRecruitingNCT05992597Phase 2
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingNCT05990465Phase 1
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaRecruitingNCT05976763Phase 3
- Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT05910801Phase 2
- "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.RecruitingNCT05888701
- Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological MalignanciesRecruitingNCT05887167Phase 1
- Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell LymphomaRecruitingNCT05868395Phase 2
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.RecruitingNCT05833763Phase 2
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell MalignanciesRecruitingNCT05780034Phase 1
- Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAvailableNCT05776134
- Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or VenetoclaxRecruitingNCT05724121